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PPARγ is a nuclear receptor that regulates numerous pathways including cytokine expression and immune responses and plays
an important role in controlling colon inﬂammation. We aimed at determining the occurring PPARγ SNPs, at predicting the
haplotypes, and at determining the frequency outcome in inﬂammatory bowel disease (IBD) patients in comparison with healthy
controls. We determined genetic variants in the coding exons and ﬂanking intronic sequences of the NR1C3 gene in 284 IBD
patients and 194 controls and predicted NR1C3 haplotypes via bioinformatic analysis. We investigated whether certain NR1C3
variants are associated with susceptibility to IBD or its disease course. None of the detected 22 NR1C3 variants were associated
with IBD. Two variants with allelic frequencies over 1% were included in haplotype/diplotype analyses. None of the NR3C1
haplotypes showed association with IBD development or disease course. We conclude that NR1C3 haplotypes are not related
to IBD susceptibility or IBD disease activity.
1.Introduction
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic
recurrent forms of inﬂammation of the gastrointestinal tract
(inﬂammatory bowel disease, or IBD), which are character-
izedbyanonsetinyoungadulthoodandbyanunpredictable
disease course that may lead to debilitating complications
[1]. The combined prevalence of CD and UC is estimated to
be 100 to 200 per 100000 individuals in developed countries
[2]. IBD is thought to be of multifactorial genesis including a
complex interplay among genetic, environmental, microbial,
andimmunefactors[3].Theexactmolecularpathogenesisof
IBD is not yet fully elucidated [4]. Although great advances
have been made in the clinical management of IBD, curative
therapeutic strategies do not exist.
It has been recognized that components of pro- and anti-
inﬂammatory signalling cascades seem to play an important
role in the pathogenesis of IBD. Initially, pro- and anti-
inﬂammatory cytoplasmic receptors that are activated by
bacterial lipopolysaccharides, such as nucleotide oligomeri-
sation domain (NOD) 2/caspase recruitment domain
(CARD) 15, and NOD1/CARD4, have been especially stud-
ied in the past and have been identiﬁed as IBD susceptibility
genes. These ﬁndings emphasized the pivotal role of an
interaction between enteric microbes and the intestinal
immune system in the pathophysiology of IBD [5–8].
Current evidence suggests that an additional receptor,
PPARγ, plays an important role in the regulation of colon
inﬂammation. PPARγ belongs to the nuclear receptor family
that consists of approximately 50 diﬀerent transcription fac-
tors, which are known to be involved in the regulation of a
wide range of diﬀerent biological processes. PPARγ con-
trols the expression of a large number of diﬀerent genes
and was initially identiﬁed as an important regulator of
genes involved in lipid metabolism and insulin sensitisation
[9]. PPARγ acts through heterodimerisation with another
nuclear receptor, retinoid X receptor α (RXRα). The het-
erodimer binds to speciﬁc DNA response elements within
the promoters of its target genes (peroxisome proliferator
response elements, PPREs) [10]. PPARγ is mostly expressed
in adipose tissue and the large intestine. Kidney, liver, and
small intestine express intermediate levels, whereas PPARγ is
barely found in muscle [11].
PPARγ is known to modulate the expression of key
transcription factors and kinases involved in inﬂammatory
signalling cascades such as NF-κB, c-Jun, c-Fos, and nuclear2 PPAR Research
Table 1: Demographic characteristics of IBD patients and non-IBD controls.
Patient cohort
UC CD IBD total
N (%) of patients 140 (49.3) 144 (50.7) 284 (100)
Male/female N (%) 77 (54.6)/64 (45.4) 77 (55)/63 (45) 140 (49.3)/144 (50.7)
Age at enrolment 44.02 ±14.69 38.59 ±14.95 41.27 ±15.04
Disease location N (%)
Available for 110 UC patients: Available for 125 CD patients
(Montreal classiﬁcation)
E1: 11 (10%) L1: 33 (26.4%)
E2: 58 (52.7%) L2: 42 (33.6%)
E3: 41 (37.3%) L3: 46 (36.8%)
L4: 4 (3.2%)
EIM frequency N (%) Available for 139 UC patients: Available for 142 CD patients: Available for 281 IBD patients:
51 (36.7) 72 (50.7) 123 (43.8)
Fistula frequency N (%) Available for 140 UC patients: Available for 144 CD patients: Available for 284 IBD patients:
10 (7.1) 73 (50.7) 83 (29.2)
Mean CDAI at enrolment NA Available for 127 CD
patients: 110.56 ±75.81 NA
State of CD
(quiescent/acute) N (%) NA
Available for 127 CD pat.:
NA
95 (74.8)/32 (25.2)
Mean mtwsi at enrolment Available for 140 UC
patients: 4.69 ±4.31 NA NA
State of UC
(inactive/active) N (%) 118 (84.3)/22 (15.7) NA NA
Leucocytes at enrolment Valid for 134 UC patients:
17.45 ±79.29
Available for 142 CD
patients: 8.9 ±7.85
Available for 276 IBD patients:
13.05 ±55.59
CRP at enrolment Valid for 127 CD patients:
9.58 ±15.31
Available for 138 CD
patients: 12.23 ±22.64
Available for 265 IBD patients:
10.96 ±19.48
Control cohort
Control total
N of controls (%) 194 (100)
Male/female N (%) 77 (39.7)/117 (60.3)
Age at enrolment 41.01 ±16.5
N: absolute number; E1: rectal UC; E2: left-sided UC; E3: extensive UC; L1: ileal CD; L2: colonic CD; L3: ileocolonic CD; L4: CD of upper GI; EIMs:
extraintestinal manifestations; CDAI: Crohn’s activity index; mtwsi: modiﬁed Truelove Witts severity index.
factor of activated T cell (NFAT). Thereby, PPARγ is able
to inhibit the mucosal production of proinﬂammatory
cytokines, such as interleukin 1β (IL-1β) and tumor necrosis
factor-α (TNFα), and to downregulate the expression of
variousadhesionmolecules[12,13].Basedontheseﬁndings,
it has been demonstrated in mouse models that activation
of PPARγ leads to an eﬃcient reduction of the severity of
intestinal inﬂammation by suppressing excessive immunoin-
ﬂammatory responses [14, 15]. As a consequence, PPARγ is
currently under investigation as a potential target for novel
anti-inﬂammatory agents [9]. Because of its central role
in the regulation of colon inﬂammation, we hypothesized
that PPARγ could be a putative susceptibility gene for the
development of IBD. The PPARγ gene NR1C3 is located on
chromosome3andiscomposedof9exons.Alternativesplic-
ing yields three diﬀerent protein isoforms, PPARγ1,PPARγ2,
and PPARγ3, which diﬀer in the amino acid composition
at their 5  ends. The isoform PPARγ2 is the most abundant
PPARγ protein found in a number of human tissues [11].
PPARγ is known to be polymorphically expressed. Several
SNPs have been described, one of which has been shown
to have consequences for both the conformational protein
structure and protein function [16, 17]. So far, only a few
studies have assessed the role of a few discrete NR1C3 gene
polymorphisms in IBD pathogenesis. A systematic study to
comprehensively investigate the role of global polymorphic
features of the NR1C3 gene with a focus on its role in IBD
susceptibility, such as the one presented here, has not been
previously performed.
In the present study, we aimed at determining all
occurring mutations and SNPs in the exonic regions of
the PPARγ gene NR1C3, at bioinformatically predicting thePPAR Research 3
Table 2: Genetic variants detected in NR1C3.
SNP no. Position in
DNA(a)
Exon/
intron no. Exon position Intron/
exon
Base
exchange
Position in
RNA(b) AA exchange(c) SNP database
1 12332979 1 Intron G>T NA Not found
2 12333068 1 Exon insC 68 frame shift Not found
3 12333070 1 5-prime C>T 70 5-prime Not found
4 12333125 1 12333001–12333173 Exon C>G 125 12 P [Pro]>A [Ala] rs1801282
5 12333199 1 Intron T>G NA Not found
6 12333213 1 Intron G>A NA Not found
7 12361272 2 12361203–12361430 Exon C>T 243 51 S [Ser]>F [Phe] Not found
8 12361422 2 Exon A>G 393 101 E [Glu]>G [Gly] Not found
9 12363017 3 12362821–12362990 Intron A>G NA Not found
10 12374014 4 Intron G>T NA Not found
11 12374024 4 Intron A>T NA Not found
12 12374091 4 Intron C>A NA rs4135333
13 12374110 4 Intron C>T NA Not found
14 12374272 4 12374113–12374251 Intron A>T NA rs4135334
15 12374352 4 Intron C>T NA Not found
16 12387616 5 12387381–12387580 Intron G>A NA Not found
17 12398613 6 12398203–12398653 Exon C>T 1321 410 S [Ser]>S [Ser] Not found
18 12415473 7 Exon G>A 1438 449 L [Leu]>L [Leu] Not found
19 12415557 7 12415397–12415855 Exon C>T 1522 477 H [His]>H [His] rs3856806
20 12415581 7 Exon G>A 1546 485K [Lys]>K [Lys] Not found
21 12415647 7 Exon G>A 1611 506 stop>stop Not found
22 12415669 7 3  end C>T3   end Not found
no.: number; AA: amino acid; (a)DNA reference sequence NT 02257.18; (b)RNA reference sequence NM 015869.4; (c)protein reference sequence P37231
(PPARG HUMAN) SWISSPROT database.
arising haplotypes, and at evaluating their association with
the risk to develop IBD and with IBD activity in a well-sized
cohort of IBD patients and non-IBD controls.
2.MaterialsandMethods
2.1. Patients. Two hundred and eighty-four clinically diag-
nosed Swiss IBD patients (140 UC and 144 CD patients)
were recruited at the centers participating in the Swiss
Inﬂammatory Bowel Disease Cohort Study (SIBDCS) [18].
All patients gave their informed consent to the inclusion
into the study. An ethical approval was obtained from
the Medical Ethical Committees of the University Hospital
Lausanne, Switzerland, and all local study sites. EDTA blood
samples were stored at the central tissue repository at the
Institute of Pathology, University of Bern, Switzerland. The
SIBDCS data center at the University Hospital of Lausanne,
Switzerland, provided data on demographics and past and
current disease characteristics. Diagnosis of IBD (CD or
UC) was conﬁrmed by the study investigations based on
clinical presentation, endoscopic ﬁndings, and histology.
Demographic and clinical information on IBD patients is
summarized in Table 1.
2.2. Control Subjects. One hundred and ninety-four non-
IBD controls were recruited from gastroenterological
patients undergoing surveillance colonoscopy, who did not
show any symptoms of IBD. History of colorectal cancer was
usedasanexclusioncriterionforbothIBDpatientsandnon-
IBD controls. All subjects provided their written informed
consent to be included in the study. Ethical approvals were
obtained from the local medical ethical committees of all
study sites involved in the collection of non-IBD samples.
2.3. Sequencing Reactions. DNA was extracted from EDTA-
blood or intestinal biopsies using the QIAcube robotic
workstation and a standard procedure (QIAamp DNA
Mini Kit, QIAGEN, Switzerland). The PCR and sequencing
primer design was based on the NCBI reference sequence
for NR1C3 (GenBank accession number NT 022175.18).
Primers for genomic DNA were designed to span all 7
exons expressed in case of the most often occurring PPARγ
protein variant 2 including at least 50bp of ﬂanking intronic
sequences at both 5  and 3  ends. The DNA sequences of
puriﬁed PCR fragments were obtained with an ABI 3730xl
sequencing machine. Details of the PCR primers can be
found in the Supplemental Table 1 available online at
doi:10.1155/2012/349469. Optimized PCR conditions, and
methods used for subsequent puriﬁcation, and sequencing
of the fragments are available upon request.
2.4. Statistical Analysis of Allele Frequencies and Genotype
Distributions. To detect diﬀerences in SNP distribution
between case and control groups or between disease activity4 PPAR Research
Table 3: Allele frequencies in IBD cases and healthy controls.
SNP no. Position in
NT 02257.18∗
IBD cases Controls
N alleles included N variant alleles Allele frequency
in % N alleles included N variant alleles Allele frequency
in %
1 12332979G>T 566 0 0 364 1 0.27
2 12333068insC 566 1 0.18 364 0 0
3 12333070C>T 566 0 0 364 2 0.55
4 12333125C>G 566 60 10.60 364 50 13.74
5 12333199T>G 566 1 0.18 364 0 0
6 12333213G>A 566 0 0 364 3 0.82
7 12361272C>T 562 1 0.18 358 0 0
8 12361422A>G 562 0 0 358 1 0.28
9 12363017A>G 554 1 0.18 334 0 0
10 12374014G>T 554 1 0.18 348 0 0
11 12374024A>T 564 1 0.18 348 0 0
12 12374091C>A 554 1 0.18 348 0 0
13 12374110C>T 554 1 0.18 348 0 0
14 12374272A>T 554 1 0.18 348 1 0.29
15 12374352C>T 554 0 0 348 1 0.29
16 12387616G>A 562 1 0.18 360 0 0
17 12398613C>T 546 0 0 370 1 0.27
28 12415473G>A 546 0 0 350 1 0.29
19 12415557C>T 546 66 12.09 350 46 13.14
20 12415581G>A 546 0 0 350 1 0.29
21 12415647G>A 546 2 0.37 350 0 0
22 12415669C>T 546 0 0 350 1 0.29
no.: number; N: absolute number; ∗DNA reference sequence signature in NCBI.
groups, the Chi-Square test or the Fisher’s exact test was
used. A P value of <0.05 was considered as signiﬁcant in
noncorrected statistical tests and of <0.0023 after correction
for multiple testing of 22 variants (according to Bonferroni).
Diﬀerences in CDAI (Crohn’s disease activity index), mtwsi
(modiﬁed Truelove Witts severity index), or CRP (C-
reactive protein) means in dependency of the genotype were
calculated using the Mann-Whitney U test. The statistical
analysis was performed using the software package SPSS 19
(SPSS Inc., Chicago, IL).
2.5. Haplotype and Diplotype Analysis. The FAMHAP soft-
ware was used to calculate the haplotypes and diplotypes
based on the detected SNPs and mutations in the NR1C3
gene and to detect diﬀerences in haplotypes and diplotype
distributions in case and control groups. FAMHAP performs
a permutation test on associations between estimated haplo-
types and the aﬀection state based on Monte Carlo simula-
tions. A value of P<0.05 was considered to be signiﬁcant.
Haplotype and diplotype calculations were performed on
256 IBD patients and 148 non-IBD controls, from which all
sequence data of adequate quality were obtained. To allow
referral to speciﬁc haplotypes, a frequency-based priority
criterion was used to name haplo- and diplotypes (e.g., H 1
or D 1 for the most often occurring haplotype or diplotype,
Table 8).
2.6. Calculation of Linkage Disequilibria. Linkage disequi-
libria (LD) were calculated using the r2 statistics. Calcula-
tions were performed using the software package Haplo-
view (http://www.broadinstitute.org/scientiﬁc-community/
science/programs/medical-and-population-genetics/haplo-
view/haploview).
3. Results
3.1. NR1C3 Sequence Variability. DNA samples from 284
IBD patients (CD or UC) and 194 healthy controls were
initially sequenced for the seven NR1C3 splice variant 2
coding exons including at least 50bp of the neighbouring
intronic sequences. The sequencing results of 256 IBD
patients (126 UC and 130 CD patients) and of 148 healthy
controls were of adequate quality and complete for all seven
exons to be further used in haplotype analyses.Table 1 shows
the demographic data of the individuals included into the
NR1C3 analysis.
The sequence data were screened for genetic variation
in the NR1C3 gene, using the Basic Local Alignment Search
Tool (BLAST; http://www.ncbi.nih.gov) and the GenBank
entry NT 02257.18 as the reference sequence. As shown in
Tables 2 and 3, altogether 22 variants were detected, which—
with exception of one mutation (one individual was foundPPAR Research 5
Table 4: Number of variant carriers in IBD and in non-IBD controls.
SNP
SNP carriers in IBD SNP carriers in controls
OR (CI) P(a)
N of subjects N (%) of variant carriers N of subjects N (%) of variant carriers
12332979G>T 283 0 (0) 182 1 (0.5) NA 0.39
12333068insC 283 1 (0.4) 181 0 (0) NA 0.61
12333070C>T 283 0 (0) 181 1 (0.6) NA 0.39
12333125A>G 283 58 (20.5) 182 48 (26.4) 0.72 0.14(b),(c)
12333125A>G 227 Hom only: 2 (0.9) 136 Hom only: 2 (1.5) 0.60 0.63(c)
12333199T>G 283 1 (0.4) 181 0 (0) NA 0.61
12333213G>A 283 0 (0) 182 3 (1.6) NA 0.06
12361272C>T 281 1 (0.4) 179 0 (0) NA 0.61
12361422A>G 281 0 (0) 179 1 (0.6) NA 0.39
12363017A>G 277 1 (0.4) 167 0 (0) NA 0.62
12374014G>T 280 1 (0.4) 174 0 (0) NA 0.62
12374024A>T 280 1 (0.4) 174 0 (0) NA 0.62
12374091C>A 280 1 (0.4) 174 0 (0) NA 0.62
12374110C>T 280 1 (0.4) 174 0 (0) NA 0.62
12374272A>T 280 1 (0.4) 174 1 (0.6) 0.62 0.62
12374352C>T 280 0 (0) 174 1 (0.4) NA 0.38
12387616G>A 282 1 (0.4) 179 0 (0) NA 0.61
12398613C>T 281 0 (0) 185 1 (0.5) NA 0.40
12415473G>A 273 0 (0) 175 1 (0.6) NA 0.39
12415557C>T 273 63 (23.1) 175 42 (24) 0.95 0.82(b),(c)
12415557C>T 213 Hom only: 3 (1.4) 137 Hom only: 4 (2.9) 0.48 0.44(c)
12415581G>A 273 0 (0) 175 1 (0.6) NA 0.39
12415647G>A 273 2 (0.7) 175 0 (0) NA 0.37
12415669C>T 273 0 (0) 175 1 (0.6) NA 0.39
OR: odds ratio; CI: conﬁdence interval; no.: number; N: absolute number; het: heterozygous; hom: homozygous; NA: not applicable; (a)P values calculated
with Fisher’s exact test; (b)P v a l u ec a l c u l a t e dw i t hC h i - S q u a r et e s t ;(c)12333125A>G: adjusted for age and sex: P = 0.14 (OR 0.72 C.I. (0.46–1.11)) (het +
hom); P = 0.53 (hom. only); 12415557C>T: adjusted for age and sex: P = 0.76 (OR 0.93 C.I. (0.59–1.46)) (het + hom), P = 0.35 (OR 0.7 C.I. (0.33–1.49))
(hom only).
to be homozygous for variant number 6)—were in Hardy-
Weinberg equilibrium. The majority of variants were single-
nucleotide substitutions. Only one variant was characterised
byabase-pairinsertionleadingtoaframeshift.Themajority
of variants have not yet been described in the NCBI SNP
database. Nine variants were found in exonic regions, 11
variants were found in intronic regions, one variant was
detected in the 5 -prime region, and 1 variant was found
within the 3  end of NR1C3. Only two of the detected vari-
ants(no.1andno.7,Table 2)leadtononsynonymousamino
acid exchanges within the PPARγ protein. Furthermore, only
two variants occurred with an allelic frequency of more
than one percent (rs1801282 and rs3856806), thus fulﬁlling
a deﬁnition of a genetic polymorphism (Table 3).
The two most often occurring variants rs1801282 and
rs3856806 were found to be in moderately strong linkage
(Figure 1, r2 = 40%, SNP numbers 4 and 19) This ﬁnding
is in good agreement with previous publications [19–21].
With the exception of two individuals, who were carriers of
mutation numbers 18 and 20 or 7 and 10 in combination, no
subject ever carried more than one rare NR1C3 variant.
3.2. Distribution of Allele and Genotype Frequencies within
IBDPatientandHealthyControlGroup. AsshowninTable 3,
only two variants (rs1801282 and rs3856806)o c c u r r e di na n
allele frequency higher than 1% in IBD and non-IBD control
group. No signiﬁcant diﬀerences in allele frequencies were
observed.
Table 4 shows the results when comparing the frequency
of NR1C3 genotypes carrying distinct genetic variants in
heterozygous or homozygous form in IBD patients and non-
IBD controls. No signiﬁcant diﬀerences in the distribution6 PPAR Research
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Figure 1: The LD plot for all NR1C3 variants that were found in the non-IBD control group. r2 = 0 (white), 0 <r 2 < 100 (shadows of
grey), and r2 = 100 (black). Numbers within squares: r2 values (0–100%), LD: linkage disequilibrium.
Table 5: Number of variant carriers (12333125A>G and 12415557C>T) in CD and UC patients compared to controls.
Category 12333125A>G
Genotype N(a) N (%) of SNP carriers OR (C.I.) P(c) OR (C.I)(b) P(b)
CD Het plus hom 143 28 (19.6) 0.68
(0.40–1–15) 0.15(d) 0.67 (0.40–1.14) 0.14
control Het plus hom 182 48 (26.4)
CD hom 116 1 (0.9) 0.58 (0.05–6.51) 1.0 0.77 (0.23–2.61) 0.68
control hom 136 2 (1.5)
UC Het plus hom 140 30 (21.4) 0.76 (0.45–1.28) 0.31(d) 0.78 (0.46–1.32) 0.35
control Het plus hom 182 48 (26.4)
UC hom 111 1 (0.9) 0.61 (0.06–6.81) 1.0 0.70 (0.21–2.38) 0.57
control hom 136 2 (1.5)
12415557C>T
CD Het plus hom 139 31 (22.3) 0.91 (0.54–1.54) 0.72(d) 0.92 (0.54–1.56) 0.74
control Het plus hom 175 42 (24.0)
CD hom 109 1 (0.9) 0.31 (0.03–2.80) 0.39 0.54 (0.18–1.62) 0.27
control hom 137 4 (2.9)
UC Het plus hom 134 32 (23.9) 0.99 (0.59–1.68) 0.98(d) 0.94 (0.55–1.62) 0.83
control Het plus hom 175 42 (24.0)
UC hom 104 2 (1.9) 0.65 (0.12–3.63) 0.70 0.84 (0.35–1.99) 0.69
control hom 137 4 (2.9)
OR: odds ratio; CI: conﬁdence interval; N: absolute number; het: heterozygous; hom: homozygous; (a)absolute number of all patients of the respective
subgroup included into the analysis; (b)adjusted for age and sex; (c)P values calculated with Fisher’s exact test; (d)P value calculated with Chi-Square test.PPAR Research 7
Table 6: Impact of variant 12333125A>G on disease activity.
Category 12333125A>G
Genotype N(a) N (%) of SNP carriers OR (C.I.) P OR (C.I.)(b) P(b)
Fistula Het plus hom 83 15 (18.1) 1.24 (0.64–2.39) 0.52 1.25 (0.65–2.4) 0.51
No Fistula Het plus hom 200 43 (21.5)
Fistula hom 68 0 (0.0) NA 1(c) NA 1
No Fistula hom 159 2 (1.3)
EIM Het plus hom 122 23 (18.9) 1.23 (0.68–2.21) 0.5 1.22 (0.67–2.21) 0.51
No EIM Het plus hom 158 35 (22.2)
EIM hom 100 1 (1.0) 0.81 (0.05–13.03) 1(c) 0.87 (0.22–3.54) 0.85
No EIM hom 124 1 (0.8)
Nonactive UC Het plus hom 118 26 (22.0) 0.79 (0.25–2.53) 0.79 0.89 (0.27–2.96) 0.85
active UC(d) Het plus hom 22 4 (18.2)
NonActive UC hom 93 1 (1.1) NA 1(c) NA 1
active UC hom 18 0 (0.0)
Quiescent CD Het plus hom 94 17 (18.1) 1.51 (0.58–3.93) 0.4 1. 47 (0.56–3.88) 0.44
Acute CD(d) Het plus hom 32 8 (25.0)
Quiescent CD hom 78 1 (1.3) NA 1(c) NA 1
Acute CD hom 24 0 (0.0)
N: absolute number; OR: odds ratio; CI: conﬁdence interval; het: heterozygous; hom: homozygous; NA: not applicable; EIMs: extraintestinal manifestations
(a)absolute number of subjects included into the respective analysis; (b)OR and P v a l u ea d j u s t e df o ra g ea n ds e x ;(c)P value calculated with Fisher’s exact test
(otherwise Chi- Square test was used); (d)a threshold of CDAI = 150, and an mtwsi of 10 points was evaluated as the beginning of active disease.
Table 7: Impact of variant 12415557C>T on disease activity.
Category
12415557C>T
Genotype N(a) N (%) of SNP
carriers OR (C.I.) P OR (C.I.)(b) P(b)
Fistula Het plus hom 79 18 (22.8) 1.02 (0.55–1.9) 0.94 1.04 (0.56–1.95) 0.89
No Fistula Het plus hom 194 45 (23.2)
Fistula hom 62 1 (1.6) 0.89 (0.07–9.2) 1(c) 0.89 (0.26–3.01) 0.85
No Fistula hom 151 2 (1.3)
EIM Het plus hom 116 26 (22.4) 1.10 (0.62–1.94) 0.76 1.09 (0.61–1.93) 0.78
No EIM Het plus hom 154 37 (24.0)
EIM hom 92 2 (2.2) 0.39 (0.03–4.31) 0.58 0.65 (0.19–2.2) 0.49
No EIM hom 118 1 (0.8)
Nonactive UC Het plus hom 114 28 (24.6) 0.77 (0.24–2.49) 0.78 0.89 (0.27–2.99) 0.86
active UC Het plus hom 20 4 (20.0)
Nonactive UC hom 87 1 (1.1) 5.30 (0.32–90–42) 0.3 3.28 (0.74–14.49) 0.12
active UC hom 17 1 (5.9)
Quiescent CD Het plus hom 91 21 (23.1) 1.16 (0.45–2.97) 0.76 1.22 (0.47–3.17) 0.68
Acute CD Het plus hom 31 25.8 (31)
Quiescent CD hom 71 1 (1.4) NA 1(c) NA 1
Acute CD hom 23 0 (0)
N: absolute number; OR: odds ratio; CI: conﬁdence interval; het: heterozygous; hom: homozygous; NA: not applicable; (a)absolute number of subjects
included into the respective analysis; (b)OR and P v a l u ea d j u s t e df o ra g ea n ds e x ;(c)P value calculated with Fisher’s exact test (otherwise Chi-Square test was
used).
of variant carriers were observed. In case of the often
occurring SNPs rs1801282 and rs3856806, we investigated
also the variant carrier frequency outcome after stratiﬁcation
according to disease subgroup (CD or UC) and diﬀerent
disease activity parameters, such as ﬁstula state, occurrence
of extraintestinal manifestations (EIMs) and overall clinical
disease activity as evaluated by the disease activity indices
CDAI and mtwsi. As demonstrated in Tables 5, 6 and 7,n o n e
of the mentioned factors were signiﬁcantly associated with
the occurrence of variants rs1801282 or rs3856806.8 PPAR Research
Table 8: Haplotype and diplotype distribution in IBD cases and non-IBD controls.
Subjects included H1 (CC)(a) H2 (CT) H3 (GC) H4 (GT) P(c)
IBD N (%) 256 436.3 (85.2) 41.3 (8.1) 12.7 (2.5) 21.7 (4.2) 0.23
OR (C.I.) 1.27 (0.87–1.86) 0.86 (0.52–1.42) 0.5 (0.23–1.07) 1.1 (0.53–2.28)
UC N (%) 126 212.6 (84.4) 22.6 (9) 6.4 (2.5) 10.4 (4.1) 0.52
OR (C.I.) 1.19 (0.76–1.87) 0.96 (0.54–1.72) 0.51 (0.2–1.3) 1.07 (0.45–2.51)
CD N (%) 130 223.6 (86) 18.6 (7.2) 6.4 (2.5) 11.4 (4.4) 0.31
OR (C.I.) 1.36 (0.86–2.15) 0.75 (0.41–1.39) 0.49 (0.19–1.26) 1.13 (0.49–2.6)
Controls 148 242.5 (81.9) 27.5 (9.3) 14.5 (4.9) 4.5 (3.9)
D1 (CC/CC)(b) D2 (CC/GT) D3 (CC/GC) D4 (CC/CT)
IBD N (%) 256 184.0 (71.9) 37.3 (14.6) 12.0 (4.7) 19.0 (7.4)
OR (C.I.) 1.3 (0.84–2.02) 0.86 (0.49–1.5) 0.51 (0.23–1.15) 1.24 (0.55–2.81)
UC N (%) 126 89.0 (70.6) 19.6 (15.6) 6.0 (4.8) 9.0 (7.1)
OR (C.I.) 1.23 (0.73–2.05) 0.93 (0.49–1.78) 0.52 (0.19–1.41) 1.19 (0.46–3.09)
CD N (%) 130 95.0 (73.1) 17.6 (13.5) 6.0 (4.6) 10.0 (7.7)
OR (C.I.) 1.39 (0.83–2.32) 0.79 (0.41–1.54) 0.5 (0.19–1.36) 1.29 (0.51–3.27)
Controls 148 98.0 (66.2) 24.5 (16.6) 13.0 (8.8) 9.0 (6.1)
D5 (CT/GT) D6 (GC/GT) D7 (GC/CT) D8 (GT/GT) P(c)
IBD N(%) 2.0 (0.8) 0.0 (0) 0.7 (0.3) 1.0 (0.4) 0.409
OR (C.I.) 0.58 (0.08–4.12) — — —
UC N (%) 1.0 (0.8) 0.0 (0) 0.0 (0) 1.0 (0.8) 0.716
OR (C.I.) — — —
CD N (%) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.588
OR (C.I.) — — —
Controls 2.0 (1.4) 1.0 (0.7) 0.5 (0.3)(d) 0.0 (0)
OR: odds ratio; CI: conﬁdence interval; N: absolute number; H1–H4: haplotype 1—haplotype 4; D1–D8: diplotype 1—diplotype 8; (a)the ﬁrst base denotes
the outcome at position rs1801282, the second base denotes the outcome at position rs1801282; (b)each base pair (before and after the slash) denotes one
haplotype; (c)P values calculated with FAMHAP; (d)frequency predicted to be 0.0 when comparing UC patients with controls.
Furthermore a comparison of the mean values of leuko-
cyte or CRP concentrations in plasma did not show any
signiﬁcant diﬀerences between IBD patients carrying the
variant rs1801282 or rs3856806 and non-variant carriers
within the patient group (data not shown).
3.3. Haplotype and Diplotype Analysis. The two NR1C3
genetic variants rs1801282 and rs3856806, which occurred
in an allele frequency of higher than 1%, were included in
the bioinformatic haplotype prediction using the computer
programme FAMHAP. For this analysis, all individuals were
considered, for which the sequencing outcome of all 22
variant loci was complete. Thus, it was possible to include
256 IBD patients (126 UC and 130 CD patients) and 148
controls. As shown in Table 8, four haplotypes (H1 to H4)
were predicted to be in best reconstruction for both cohorts
leadingtoeightdiﬀerentputativelyoccurringdiplotypes(D1
to D8). All haplotypes and ﬁve diplotypes were predicted to
occur at a frequency higher than 1% in the non-IBD control
group.
Neither the overall haplotype nor the overall diplotype
pattern varied signiﬁcantly between the IBD group (or the
IBD subgroups) and the control group. The result remained
non-signiﬁcant when investigating a possible relationship
between the occurring haplotype or diplotype distribution
pattern and disease activity (abundance of EIMs, ﬁstulas, or
high activity indices; Tables 9–11).
4. Discussion
PPARγ is an important modulator of pro- and anti-
inﬂammatory signalling cascades involving NF-κB. The
importance of PPARγ is underlined by the fact that eﬃcient
anti-inﬂammatory eﬀects can be reached when targeting
PPARγ therapeutically. An important example of an anti-
inﬂammatory acting drug, which exerts agonistic eﬀects on
PPAR-γ and which is widely used in the therapy of especially
UC is 5-aminosalicylic acid (5-ASA) [22].
Former studies, which investigated the impact of a
polymorphic expression of PPARγ on diseases characterized
by proinﬂammatory processes, focused speciﬁcally only on
the analysis of the two commonly occurring NR1C3 SNPs
rs1801282 and/or rs3856806. Several investigations showed
thattheseNR1C3genevariantsareputativelyassociatedwith
a moderately higher risk for the development of lifestyle-
associated diseases (e.g., metabolic syndrome, coronaryPPAR Research 9
Table 9: Haplotype and diplotype distribution in IBD cases with and without EIMs.
Subjects included H1 (CC) H2 (CT) H3 (GC) H4 (GT) P(a)
IBD N (%)
110
189.8 (86.2) 10.2 (4.6) 3.2 (1.5) 16.8 (7.6)
0.57
OR (CI) 1.18 (0.72–1.95) 1.18 (0.50–2.80) 0.44 (0.12–1.58) 0.87 (0.46–1.67)
Controls(b) 143 240.7 (84.1) 11.4 (4.0) 9.3 (3.3) 24.7 (8.6)
UC N (%)
45
76.9 (85.5) 5.1 (5.6) 1.1 (1.2) 6.9 (7.7)
0.55
OR (CI) 1.15 (0.56–2.37) 1.79 (0.51–6.25) 0.36 (0.04–2.93) 0.76 (0.3–1.93)
Controls(b) 80 133.8 (83.6) 5.2 (3.2) 5.2 (3.2) 15.8 (9.9)
CD N (%)
65
112.8 (86.8) 5.2 (4.0) 2.2 (1.7) 9.8 (7.6)
0.82
OR (CI) 1.18 (0.58–2.38) 0.8 (0.24–2.66) 0.49 (0.09–2.61) 1.09 (0.42–2.79)
Controls(b) 63 106.8 (84.8) 6.2 (4.9) 4.2 (3.3) 8.8 (7.0)
D1 (CC/CC) D2 (CC/GT) D3 (CC/GC) D4 (CC/CT) P(a)
IBD N (%)
110
82.0 (74.5) 14.8 (13.4) 3.0 (2.7) 8.0 (7.3)
OR (CI) 1.30 (0.75–2.27) 0.82 (0.41–1.67) 0.42 (0.11–1.58) 0.94 (0.37–2.43)
Controls(b) 143 99.0 (69.2) 22.7 (15.8) 9.0 (6.3) 11.0 (7.7)
UC N (%)
45
33.0 (73.3) (13.2) 1.0 (2.2) 4.0 (8.9)
OR (CI) 1.25 (0.55–2.82) 0.73 (0.26–2.06) 0.34 (0.04–3.01) 1.46 (0.37–5.75)
Controls(b) 80 55.0 (68.8) 13.8 (17.3) 5.0 (6.3) 5.0 (6.3)
CD N (%)
65
49.0 (75.4) 8.8 (13.6) 2.0 (3.1) 4.0 (6.2)
OR (CI) 1.32 (0.61–2.88) 0.96 (0.35–2.63) 0.47 (0.08–2.65) 0.62 (0.17–2.32)
Controls(b) 63 44.0 (69.8) 8.8 (14.0) 4.0 (6.3) 6.0 (9.5)
D5 (CT/GT) D6 (GC/GT) D7 (GC/CT) D8 (GT/GT)
IBD N (%) 2.0 (1.8)
NP NP
0.0 (0) 0.36
OR (CI) — —
Controls 0.0 (0) NP NP 1.0 (0.7)
UC N (%) 1.0 (2.2)
NP NP
0.0 (0) 0.6
OR (CI) — —
Controls 0.0 (0) NP NP 1.0 (1.3)
CD N (%) 1.0 (1.5)
NP NP NP 0.73
OR (CI) —
Controls 0.0 (0) NP NP NP
OR: odds ratio; CI: conﬁdence interval; N: absolute number; H1–H4: haplotype 1—haplotype 4; D1–D8: diplotype 1—diplotype 8; EIMs: extraintestinal
manifestations; NP: predicted not to appear in the case or control group; (a)P values calculated with FAMHAP; (b)the term “controls” denotes here the
respective patient subgroup (IBD/UC/CD) without EIMs.
artery disease, and type 2 diabetes) or for colorectal cancer
[23–29]. However, these ﬁndings were only partly supported
in subsequent meta-analyses [30–32].
In the study presented here, we aimed at comprehen-
sively investigating the occurring polymorphisms within
the PPARγ gene by sequencing all exonic regions and
neighbouring intronic sequences. We analysed the frequency
of arising genotypes and haplotypes in a large cohort of IBD
patients and non-IBD control subjects and investigated the
impact of the observed NR1C3 variants on IBD susceptibility
and disease course.
Interestingly, NR1C3 appears to be strongly conserved.
Only the two genetic variants rs1801282 and rs3856806,
whichhavealreadybeendescribedintheliteratureandwhich
are characterized by a moderately strong linkage behaviour,
were found to occur in an allelic frequency of >1%. This
observation, together with the fact that all other detected
NR1C3 gene mutations occurred alone in >99% of all cases
and never in combination with other PPARγ gene variants in
any individual included in our study, supports the important
physiological function of PPARγ, which apparently does not
allow a highly polymorphic expression of this protein.
We did not ﬁnd any signiﬁcant association of distinct
NR1C3 haplotypes with higher IBD susceptibility or with
a modiﬁed IBD course. A few other studies have hitherto
investigated the impact of a polymorphic PPARγ expression10 PPAR Research
Table 10: Haplotype and diplotype distribution in IBD cases with and without ﬁstulas.
Subjects included H1 (CC) H2 (CT) H3 (GC) H4 (GT) P(a)
IBD N (%) 77 132.9 (86.3) 7.1 (4.6) 3.1 (2.0) 10.9 (7.0) 0.89
OR (C.I.) 1.13 (0.65–1.94) 1.16 (0.46–2.9) 0.77 (0.21–2.81) 0.81 (0.40–1.67)
Controls(b) 179 303.6 (84.8) 14.4 (4.0) 9.4 (2.6) 30.6 (8.5)
UC N (%) 9 17.0 (94.4) 0.0 (0.001) 0.0 (0.001) 1.0 (5.5) 0.65
OR (C.I.) 0.02 (0.0–439897.28) 0.03 (0.0–739520.9) 0.57 (0.07–4.52)
Controls(b) 117 195.8 (83.7) 10.2 (4.4) 6.2 (2.7) 21.8 (9.3)
CD N (%) 68 115.8 (85.2) 7.2 (5.3) 3.2 (2.3) 9.8 (7.2) 0.90
OR (C.I.) 0.86 (0.43–1.74) 1.6 (0.47–5.51) 0.91 (0.19–4.42) 1.02 (0.40–2.61)
Controls(b) 72 107.8 (87.0) 4.2 (3.3) 3.2 (2.5) 8.8 (7.1)
D1 (CC/CC) D2 (CC/GT) D3 (GC/CT) D4 (CC/CT) P(a)
IBD N (%) 77 57.0 (74.0) 9.9 (12.8) NP 6.0 (7.8)
OR (C.I.) 1.17 (0.64–2.13) 0.81 (0.37–1.76) 1.08 (0.39–2.95)
Controls(b) 179 127.0 (70.9) 27.6 (15.4) NP 13.0 (7.3)
UC N (%) 9 8.0 (88.9) 1.0 (11.0) NP 0.0 (0)
OR (C.I.) 3.56 (0.43–29.49) 0.65 (0.08–5.53) —
Controls(b) 117 81.0 (69.2) 18.8 (16.0) NP 9.0 (7.7)
CD N (%) 68 49.0 (72.1) 8.8 (13.0) NP 6.0 (8.8)
OR (C.I.) 0.90 (0.41–1.95) 0.90 (0.33–2.45) 1.40 (0.38–5.23)
Controls(b) 72 46.0 (74.2) 8.8 (14.3) NP 4.0 (6.5)
D5 (CC/GC) D6 (CT/GT) D7 (GT/GT) D8 (GC/GT)
IBD N (%) 3.0 (3.9) 1.0 (1.3) 0.0 (0) NP 0.98
OR (C.I.) 0.77 (0.20–2.91) — —
Controls 9.0 (5.0) 1.0 (0.6) 1.0 (0.6) NP
UC N (%) 0.0 (0) 0.0 (0) 0.0 (0) NP 0.67
OR (C.I.) — — —
Controls 6.0 (5.1) 1.0 (0.9) 1.0 (0.9) NP
CD N (%) 3.0 (4.4) 1.0 (1.5) NP NP 0.98
OR (C.I.) 0.91 (0.18–4.67) —
Controls 3.0 (4.8) 0.0 (0) NP NP
OR: odds ratio; CI: conﬁdence interval; N: absolute number; H1–H4: haplotype 1—haplotype 4; D1–D8: diplotype 1—diplotype 8; NP: predicted to not
appear in the respective case and control group; (a)P values calculated with FAMHAP; (b)t h et e r m“ c o n t r o l s ”d e n o t e sh e r et h er e s p e c t i v ep a t i e n ts u b g r o u p
(IBD/UC/CD) without the appearance of ﬁstulas.
on IBD susceptibility. These studies focused mainly on the
investigation of the Pro12Ala polymorphism (rs1801282)
and its putative inﬂuence on UC disease risk. These stud-
ies showed heterogeneous results. While [33] observing
a signiﬁcantly higher frequency of homozygous Pro12Ala
SNP carriers in UC patients compared to controls in a
Danish cohort, Shrestha et al. only observed a putative
relationship between a higher UC disease activity and the
occurrence of the Pro12Ala variant in a Dutch population,
which they could not conﬁrm in a Chinese cohort [34]. A
third study focused speciﬁcally on the functional impact of
the Pro12Ala SNP and showed that this variant appears to
be associated with lower PPARγ mRNA levels in diseased
mucosa of UC patients. This ﬁnding was combined with a
higher prevalence of the Ala-variant in UC patients, when
compared to CD patients and healthy controls. The latter
observation, however, derives from only a relatively small
number of individuals (29 UC and 10 CD patients, 134
controls), which were included in the analysis [35]. Two
additional small studies did not ﬁnd any signiﬁcant impact
of the SNP Pro12Ala on disease susceptibility for CD [36]o r
UC[37].Inthecontextoftheheterogeneousstudyoutcomes
published so far, our study rather supports the hypothesis
that a polymorphic expression of the PPARγ gene NR1C3
does not signiﬁcantly inﬂuence the IBD risk or the course
of the IBD forms, CD and UC.
5. Conclusions
In conclusion, we have performed a comprehensive study
analyzing the role of NR1C3 genetic variants in IBD suscep-
tibility and IBD course in a Swiss cohort of IBD patients. We
showed that the polymorphic expression of the PPARγ gene
is not a general modulating risk factor for IBD.PPAR Research 11
Table 11: Haplotype and diplotype distribution in IBD cases with and without disease activity.
Subjects included H1 (CC) H2 (CT) H3 (GC) H4 (GT) P(a)
IBD N (%) 48 82.9 (84.6) 3.1 (3.2) 2.1 (2.2) 9.9 (10.1) 0.83
OR (C.I.) 0.99 (0.53–1.83) 0.65 (0.19–2.21) 0.88 (0.2–3.96) 1.29 (0.6–2.74)
Controls(b) 191 323.6 (84.7) 18.4 (4.8) 9.4 (2.5) 30.6 (8.0)
UC N (%) 18 31.0 (86.0) 1.0 (2.9) 0.0 (0.1) 4.0 (11.0) 0.74
OR (C.I.) 1.16 (0.42–3.18) 0.67 (0.08–5.23) 0.04 (0.0–749.8) 1.3 (0.41–4.09)
Controls(b) 108 181.8 (84.2) 9.2 (4.3) 6.2 (2.9) 18.8 (8.7)
CD N (%) 31 51.9 (83.7) 2.1 (3.4) 2.1 (3.4) 5.9 (9.5) 0.72
OR (C.I.) 0.88 (0.39–1.95) 0.6 (0.13–2.76) 1.79 (0.31–10.5) 1.37 (0.49–3.86)
Controls(b) 83 141.8 (85.4) 9.2 (5.5) 3.2 (1.9) 11.8 (7.1)
D1 (CC/CC) D2 (CC/GT) D3 (GC/CT) D4 (CC/CT) P(a)
IBD N (%) 48 35.0 (71.4) 8.9 (18.1) NP 2.0 (4.1)
OR (C.I.) 1.04 (0.52–2.08) 1.31 (0.57–3.01) 0.44 (0.10–1.95)
Controls(b) 191 135.0 (70.7) 27.6 (14.4) NP 17.0 (8.9)
UC N (%) 18 14.0 (77.8) 3.0 (16.4) NP 0.0 (0)
OR (C.I.) 1.54 (0.47–5.03) 1.07 (0.28–4.13) —
Controls(b) 108 75.0 (69.4) 16.8 (15.5) NP 9.0 (8.3)
CD N (%) 31 21.0 (67.7) 5.9 (19.0) NP 2.0 (6.5)
OR (C.I.) 0.81 (0.33–1.97) 1.57 (0.52–4.72) 0.65 (0.13–3.23)
Controls(b) 83 60.0 (72.3) 10.8 (13.0) NP 8.0 (9.6)
D5 (CC/GC) D6 (CT/GT) D7 (GT/GT) D8 (GC/GT)
IBD N (%) 2.0 (4.1) 1.0 (2.0) 0.0 (0) NP 0.70
OR (C.I.) 0.86 (0.18–4.12) — —
Controls 9.0 (4.7) 1.0 (0.5) 1.0 (0.5) NP
UC N (%) 0.0 (0) 1.0 (5.6) 0.0 (0) NP 0.16
OR (C.I.) — — —
Controls 6.0 (5.6) 0.0 (0) 1.0 (0.9) NP
CD N (%) 2.0 (6.5) 0.0 (0) NP NP 0.80
OR (C.I.) 1.84 (0.29–11.57) —
Controls 3.0 (3.6) 1.0 (1.2) NP NP
OR: odds ratio; CI: conﬁdence interval; N: absolute number; H1–H4: haplotype 1—haplotype 4; D1–D8: diplotype 1—diplotype 8; NP: predicted to not
appear in the respective case or control group; (a)P values calculated with FAMHAP; (b)the term “controls” denotes here the respective patient subgroup
(IBD/UC/CD) without the respective ongoing disease activity pattern investigated.
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